Jessica Merrill
Senior Editor
Latest From Jessica Merrill
Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say
The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.
Blockbusters By Indication: More Begets More
A Scrip analysis of the industry’s top-selling drugs examines the power of indication expansion to drive revenue growth.
The Life Of A Blockbuster
The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs to see which are forecast to make the most at peak and over a 14-year time horizon.
Gene Therapy Q1 Roundup: The Struggle Is Real
Vertex and bluebird compete for sickle cell patients, BioMarin talks about divesting Roctavian, and Sarepta warned that sales of Elevidys will plateau with a narrow label.
Teva Starts The Year With Phase III Data And Growth
Teva reported positive Phase III data for a long-acting version of olanzapine for schizophrenia, coinciding with its first quarter sales and earnings release.
With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way
The company initiated a rolling NDA submission for suzetrigine for acute pain, positioning the drug for a launch in 2025.